Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 2, 2005, Pages 103-110

  Poulsen, Tina Svenstrup ^a   Vinholt, Pernille ^a   Mickley, Hans ^a   Korsholm, Lars ^b   Kristensen, Søren Risom ^a   Damkier, Per ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 3A4; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PRODRUG; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG ANTAGONISM; DRUG METABOLISM; EX VIVO STUDY; HEART INFARCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MORTALITY; MYALGIA; MYOPATHY; PRIMARY PREVENTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SECONDARY PREVENTION; SHORT SURVEY; STATISTICAL SIGNIFICANCE; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS; MULTICENTER STUDIES; PRODRUGS; PYRROLES; TICLOPIDINE;

EID: 14644439816     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto960203.x     Document Type: Short Survey

References (34)

1. Bertrand, M. E., H. J. Rupprecht, P. Urban & A. H. Gershlick: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000, 102, 624-629.
2. Borries, M., M. Heins, Y. Fischer, H. Stiegler, A. Peters, H. Reinauer, F. C. Schoebel, B. E. Strauer & M. Leschke: Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. J. Amer. Coll. Cardiol. 1999, 34, 486-493.
3. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet 1996, 348, 1329-1339.
4. Clarke, T. A. & L. A. Waskell: The metabolism of clopidogrel is catalysed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Disp. 2003, 31, 53-59.
5. CURE Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. New Engl. J. Med. 2001, 345, 494-502 [Errata, New Engl. J. Med. 2001, 345, 1506 & 1716].
6. CURE Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. New Engl. J. Med. 2001, 345, 494-502 [Errata, New Engl. J. Med. 2001, 345, 1506 & 1716].
7. Gurbel, P. A., C. C. Cummings, C. R. Bell, A. B. Alford, A. F. Meister & V. L. Serebruany: Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the plavix reduction of new thrombus occurrence (PRONTO) trial. Amer. Heart J. 2003a, 145, 239-247.
8. Gurbel, P. A., K. P. Bliden, B. L. Hiatt & C. M. O'Connor: Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pre-treatment platelet reactivity. Circulation 2003b, 107, 2908-2913.
9. Horsmans, Y.: Differential metabolism of statins: importance in drug-drug interactions. Eur. Heart J. Supplements 1999, 1 (Suppl T), T7-T12.
10. Ishigami, M., T. Honda, W. Takasaki, T. Ikeda, T. Komai, K. Ito & Y. Sugiyama: A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab. Disp. 2001, 29, 282-288.
11. Jacobsen, W., G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K. F. Sewing & U. Christians: Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Disp. 1999, 27, 173-179.
12. Jacobsen, W., B. Kuhn, A. Soldner, G. Kirchner, K. F. Sewing, P. A. Kollman, L. Z. Benet & U. Christians: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Disp. 2000, 28, 1369-1378.
13. Kantola, T., K. T. Kivisto & P. J. Neuvonen: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Therap. 1998, 64, 58-65.
14. Lau, W. C., L. A. Waskell, C. J. Neer, D. G. M. Carville, & E. R. Bates: The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation 2000, (suppl) 102, 18, p II-429.
15. Lau, W. C., L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G. M. Carville, K. E. Guyer & E. R. Bates: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003, 107, 32-37.
16. Lau, W. C., P. A. Gurbel, P. B. Watkins, C. J. Neer, A. S. Hopp, D. G. M. Carville, K. E. Guyer, A. R. Tait & E. R. Bates: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004, 109, 166-171.
17. Lennernas, H.: Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 2003, 42, 1141-1160.
18. Martin, P. T. & R. Denman: Atorvastatin-clopidogrel interaction. Circulation 2003, 107, 223.
19. Martin, P. D., M. J. Warwick, A. L. Dane, S. J. Hill, P. B. Giles, P. J. Philips & E. Lenz: Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Therap. 2003, 25, 2822-2825.
20. Mitsios, J. V., A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos & A. D. Tselepis: Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004, 109, 1335-1338.
21. Mizuno, O., Y. Hojo & U. Ikeda: Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending artery. Amer. J. Cardiol. 2000, 85, 154-160.
22. Moshfegh, K., M. Redondo, F. Julmy, W. A. Wuillemin, M. U. Gebauer, A. Haeberli & B. J. Meyer: Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J. Amer. Coll. Cardiol. 2000, 36, 699-705.
23. Müller, I., F. Besta, C. Schulz, L. Zhongyan, S. Massberg & M. Gawaz: Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003, 108, 2195-2197.
24. Neubauer, H., B. Günesdogan, C. Hanefeld, M. Spiecker & A. Mügge: Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur. Heart J. 2003, 24, 1744-1749.
25. Prueksaritanont, T., R. Subramanian, X. Fang, B. Ma, Y. Qui, J. H. Lin, P. G. Pearson & T. A. Baillie: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Disp. 2002, 30, 505-512.
26. Savi, P., J. M. Pereillo, M. F. Uzabiaga, J. Combalbert, C. Picard, J. P. Maffrand, M. Pascal & J. M. Herbert: Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haem. 2000, 84, 891-896.
27. 12, a new platelet ADP receptor, target of clopidogrel. Biochem. Biophys. Res. Commun. 2001, 283, 379-383.
28. Saw, J., S. R. Steinbuhl, P. B. Berger, D. J. Kereiakes, V L. Serebruany, D. Brennan & E. J. Topol: For the Clopidogrel for the reduction of events during observation (CREDO) investigators. Lack of adverse clopidogrel - atorvastain clinical interaction from secondary analysis of a randomised, placebo-controlled clopidogrel trial. Circulation 2003, 108, 921-924.
29. Serebruany, V. L., A. I. Malinin, K. P. Callahan, P. A. Gurbel & S. R Steinhubl: Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 2001, 159, 239-241.
30. Shechter, M.: Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation. Circulation 2003, 107, 210.
31. Shechter, M.: Do statins really interfere with clopidogrel-induced platelet function. Eur. Heart J. 2004, 25, 448.
32. Steinhubl, S. R., P. B. Berger, J. T. 3rd. Mann, C. T. Fry, A. DeLago, C. Wilmer, E. J. Topol; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J. Amer. Med. Association 2002, 288, 2411-2420.
33. Wienbergen, H., A. K. Gitt, R. Schiele, C. Juenger, T. Heer, C. Meisenzahl, P. Limbourg, C. Bossaller & J. Senges, for the MITRA PLUS Study Group: Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Amer. J. Cardiol. 2003, 92, 285-288.
34. Williams, D. & J. Feely: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokin. 2002, 41, 343-370.